抗击新型冠状病毒肺炎的药物和治疗方案的阶段性研究进展  

Recent research for COVID-19 drugs and therapies

作　　者：邢颖 刘文彬[2] Ying Xing;Wenbin Liu(Institutes of Science and Development,Chinese Academy of Sciences,Beijing 100190,China;Research Center for Eco-Environmental Sciences,Chinese Academy of Sciences,Beijing 100085,China)

机构地区：[1]中国科学院科技战略咨询研究院,北京100190 [2]中国科学院生态环境研究中心,北京100085

出　　处：《科学通报》2020年第22期2326-2333,共8页Chinese Science Bulletin

基　　金：中国科学院生态环境研究中心城市与区域生态国家重点实验室开放基金(SKLURE2018-2-3)资助。

摘　　要：2019年底,新型冠状病毒突然肆虐,给我国乃至世界带来严峻的公共卫生危机.寻找能够对抗新型冠状病毒及其引起的肺炎等相关疾病的适用药物及治疗方案成为当务之急.基于以往治疗类似疾病的认识和经验,研究人员在最短时间提出了上百种可能的候选药物.目前已经提出并进入临床试验的几类药物包括核苷类似物、蛋白酶抑制剂、其他化学小分子药物、生物制剂等.结合传统中医药辨证治疗的中西医结合疗法展现了很好的治疗效果.研究人员正在对这些在研药物的临床效果、剂量、适应性及毒副作用开展进一步的研究验证.本文对截至2020年2月16日的医学论文数据库信息及网络资料进行了梳理,对一个月来科研人员、制药行业、临床医生提出的潜在药物和治疗方法进行了综述,希望为抗击新型冠状病毒提供参考。The sudden outbreak of COVID-19 is causing a severe health crisis to China and the world. The rapid spread coronavirus worldwide highlights the urgent need to find effective drugs and therapies to fight the COVID-19 and related diseases such as acute respiratory disease. Based on the current knowledge on the structure, pathogenic mechanism and pharmacy of coronavirus and previous understanding and experience in treating similar diseases, researchers are testing and screening the approved broad-spectrum antiviral drugs and compounds, and investigating new specific drugs aiming at curing COVID-19. Facing the coronavirus pandemic, it is essential methods and strategies to review existing broad-spectrum antiviral drugs and screen possible effective medicines through some compounds database or repository of structured medical information. Till now, scientists have proposed hundreds of possible drug candidates in a short period of time.This article summarized the potential drugs and treatments proposed by scientists, pharmaceutical industries, and clinicians through literature survey on Pub Med—a medical academic database, two clinical trials databases, and internet information published before February 16 th, 2020. Then a system review and analysis on the development situations and trends about COVID-19 drugs and therapies were carried out.According to the documents published, scientists and doctors have focused on several possible categories of drugs,including:(1) Chemical compounds, such as nucleoside analogues, protease inhibitors, and other antiviral drugs with multiple mechanisms;(2) biologics, such as monoclonal antibodies, interferon, peptides, plasma of recovered patients and some new kinds of therapies;(3) traditional Chinese medicines, such as some syndrome differentiation therapies. Now,nearly 100 agents or therapies have entered into the clinic research processes and some of them have arrived at the IV phase of clinical trials.Due to the considerable previous experiences and understands that have been ac

关 键 词：2019-nCoV COVID-19 新型冠状病毒 药物研发 临床试验 

分 类 号：R563.1[医药卫生—呼吸系统]